Login to Your Account



Other News To Note


Thursday, April 28, 2011
• Beactica AB, of Uppsala, Sweden, has entered into an agreement with Janssen Pharmaceutica NV, a subsidiary of New Brunswick, N.J.-based Johnson & Johnson, under which Beactica will use its Sprint drug discovery platform to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Financial details were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription